The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease

Interventional Study of the Effect of Parkinson Kinetigraph Recordings on the Clinical Management and Outcome in Parkinson's Disease

With time most people with Parkinson's disease (PwP) develop fluctuations in motor symptoms in relation to medication intake. The prevalence may be both under and overestimated as it is based on history rather than observation. Patterns in fluctuations are difficult to determine and it has been demonstrated that every 30-minute diaries need to be kept for 10 days or more to safely represent fluctuation patterns. The Parkinson Kinetigraph (PKG) is an automated system that is carried passively and provides similar information after wearing the device for 6 days. Clinical experience is that most patients agree that results are representative to their experiences. It is not known if using the PKG routinely at any stage of PD will change management of the disease. The hypothesis of this study is that providing PKG information to neurologists will lead to a more active management that may improve outcome in PD patients.

Study Overview

• Status: Completed
• Conditions: Parkinson Disease
• Intervention / Treatment: Other: Self assessment; Device: Parkinson KinetiGraph

Detailed Description

Patients that have previously not performed a PKG recording will be recruited from the WestPORTS community based cohort of outpatients with PD in West Sweden. The WestPORTS study includes self-assessments like PDQ8 and NMS-Q as well as PKG recordings. On inclusion in WestPORTS-Int subjects will be randomized by minimization for age, gender and disease duration into one of two study arms. In the intervention group the PKG recording of the subject will be made available, together with a summarized interpretation, to the subject's regular neurologist/geriatrician before the next scheduled visit/contact. The neurologist will also be provided with PDQ8 and NMS-Q responses. In the control group only PDQ8 and NMS-Q responses will be available to the treating neurologist/geriatrician.

At the next regular visit/contact the physician will fill out an assessment of the state of the patient, whether stable or in need of change in management. Any contraindications to changed management will be noted and the decision to change or not change management will be recorded as the primary outcome of the study. Secondary outcomes are the patient reported experience of outpatient care according to a modified version of the Generic Short Patient Experiences Questionnaire (GS-PEQ), as well as patient reported (PDQ8, NMS-Q, PRO-PD, EQ5D5L) and PKG outcomes at a time point three months later.

Change of management is defined as any of the following:

1. Adding or stopping a dopamine agonist, COMT- or MAO-inhibitor, anticholinergic or amantadine.
2. Fractionation or de-fractionation of the current daily levodopa dose
3. Change of current Levodopa Equivalent daily dose by 15% or more
4. Start or stop of night medication
5. Referral for device assisted therapy (LCIG, apomorphine pump or DBS)

Actual change of management (as opposed to decision to change) will be documented by retrospective review of medical records and prescription records. This will be a secondary measure.

• Study Type: Interventional
• Enrollment (Actual): 147
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Göteborg, Sweden, 41345
    • Sahlgrenska University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Clinical diagnosis of Parkinson's disease (ICD G209) according to medical records
2. A visit to an outpatient neurological or geriatric clinic in the region Vastra Gotaland, Sweden within the last -1 to -7 months according to medical records.
3. Randomized to invitation to participate in the WestPORTS objective measurement Cohort study (NCT03130595) by 1:4 randomization based on the full population fulfilling criteria 1 and 2.
4. Written informed consent
5. No previous PKG recording has been performed with the subject.

Exclusion Criteria:

1. Withdrawal of consent.
2. Unable to wear a PKG on either wrist.
3. The patient's physician is the PI of the study (F Bergquist)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control; Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment	Other: Self assessment; Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.; Other Names: PDQ8; NMS-Questionnaire
Experimental: Intervention; Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment	Other: Self assessment; Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.; Other Names: PDQ8; NMS-Questionnaire; Device: Parkinson KinetiGraph; The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.; Other Names: Parkinson KinetiGraph Mk II; PKG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Decision to change management	The decision to change management of Parkinson's disease as reported by the treating physician. Change of management is defined as any of the following: Adding or stopping a dopamine agonist, COMT- or MAO-inhibitor, anticholinergic or amantadine.; Fractionation or de-fractionation of the current daily levodopa dose; Change of current Levodopa Equivalent daily dose by 15% or more; Start or stop of night medication; Referral for device assisted therapy (LCIG, apomorphine pump or DBS)	On first regular contact, RC, (telephone or visit) wich takes place within four months after PKG-recording

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Actual change of management	A retrospectively verified (medical and prescription records) change in management of PD as defined in the primary variable	Change should take place within 4 weeks from the RC.
Patient Reported Experience of Care	A modified version of Generic Short Patient Experiences Questionnaire (GS-PEQ), Sjetne et al 2011 will be used. The modified questionnaire has 13 questions that are answered with a 5 grade Likert scale and a 5 grade Likert scale describing the importance of each question. Items will be analyzed separately as well as as summary scores	The assessment will be made within 3 days from the first RC after PKG-recording,
PRO-PD score at 3 months after the first regular visit	The Patient Reported Outcome in PD web questionnaire will be reported as summary score as well as per symptom domain.	The assessment is made 3 months after the RC.
PDQ-8 score at 3 months after the first regular visit	The 8 question version of Parkinson Disease Quality of Life Questionnaire. Reported as index score (0-100%)	The assessment is made 3 months after the RC.
NMSQ score at 3 months after the first regular visit	The Non Motor Symptoms Questionnaire will be administered and the number of reported symptoms within the last month are reported	The assessment is made 3 months after the RC.
EQ5D-5L at 3 months after the first regular visit	The EuroQoL 5 dimension 5 level scale of generic health	The assessment is made 3 months after the RC.
Parkinson Kinetigraph bradykinesia measurement at 3 months after the first regular visit	Median BK score of a 6 day recording.	The assessment is made 3 months after the RC.
Parkinson Kinetigraph dyskinesia measurement at 3 months after the first regular visit	Median DK score of a 6 day recording.	The assessment is made 3 months after the RC.
Parkinson Kinetigraph fluctuation score at 3 months after the first regular visit	Fluctuation dyskinesia score (FDS) of a 6 day recording.	The assessment is made 3 months after the RC.
Parkinson Kinetigraph Tremor measurement at 3 months after the first regular visit	Mean percent day-time (9-18) tremor time in a 6 day recording.	The assessment is made 3 months after the RC.
Parkinson Kinetigraph immobility measurement at 3 months after the first regular visit	Mean percent day-time (9-18) immobility time in a 6 day recording.	The assessment is made 3 months after the RC.
Change in PDQ8 compared to baseline	The change in PDQ8 index score compared to the baseline assessment that is made at the inclusion visit	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in NMSQ compared to baseline	The change in number of reported non-motor symptoms characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in EQ5D5L compared to baseline	The change in index score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in Parkinson Kinetigraph bradykinesia score compared to baseline	The change in BK score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in Parkinson Kinetigraph dyskinesia score compared to baseline	The change in DK score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in Parkinson Kinetigraph fluctuation score compared to baseline	The change in FDS score characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as abnormal score that has changed to within normal limits, no change defined as normal score that remains within normal limits and deterioration defined as normal score that changes to a score outside normal limits	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in Parkinson Kinetigraph Tremor measurement compared to baseline	The change in percent tremor time characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement defined as a decrease in tremor time which was higher than 0.9% at baseline, no change defined as tremor time that remains lower or equal to 0.9% or remains the same as at baseline. Deterioration defined as an increase in tremor time that results in a tremor time higher than 0.9% at follow up.	Assessed 3 months after the RC and at end of study 12 months after inclusion visit
Change in Parkinson Kinetigraph Immobility measurement compared to baseline	The change in percent immobility time characterized as improvement, no change, or deterioration compared to the baseline assessment that is made at the inclusion visit. Improvement is defined as a decrease in immobility time, no change is defined as immobility time that remains the same as at baseline. Deterioration defined as an increase in immobility time at follow up.	Assessed 3 months after the RC and at end of study 12 months after inclusion visit

Collaborators and Investigators

• Sponsor: Sahlgrenska University Hospital, Sweden
• Investigators: Principal Investigator: Filip Bergquist, Göteborg University

Study record dates

Study Major Dates

• Study Start (Actual): April 30, 2017
• Primary Completion (Actual): October 1, 2018
• Study Completion (Actual): February 28, 2019

Study Registration Dates

• First Submitted: May 10, 2017
• First Submitted That Met QC Criteria: May 12, 2017
• First Posted (Actual): May 15, 2017

Study Record Updates

• Last Update Posted (Actual): April 4, 2019
• Last Update Submitted That Met QC Criteria: April 2, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: Registry; motor complications; accelerometry; home based; Parkinson KinetiGraph
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: WestPORTSintervention; PARKreg (REGISTRY: Svenska Parkinsonregistret)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No